PMID- 12063810
OWN - NLM
STAT- MEDLINE
DCOM- 20020716
LR  - 20191106
IS  - 0896-4327 (Print)
IS  - 0896-4327 (Linking)
VI  - 15
IP  - 2
DP  - 2002 Apr
TI  - Low molecular weight heparins and glycoprotein IIb/IIIa antagonists.
PG  - 147-54
AB  - The consistent message that emerges from virtually every recent acute coronary 
      syndrome (ACS) trial is that the old "standard" of using aspirin and 
      unfractionated heparin (UFH) can be considerably improved upon. Low molecular 
      weight heparins (LMWHs) (most notably enoxaparin) are emerging as a broad 
      replacement for UFH. Initial safety concerns about combining LMWHs and 
      glycoprotein (GP) IIb/IIIa antagonists have not been borne out; in fact, major 
      bleeding complications may be lower with LMWHs. Clinical outcomes to date suggest 
      that LMWHs may be a better first line therapy than UFH on which to superimpose 
      adjunctive GP IIb/IIIa antagonists. Emerging clinical experience further supports 
      the safety and efficacy of this combination regimen. The forthcoming SYNERGY 
      study will prospectively compare enoxaparin and UFH in high risk patients in whom 
      an invasive management strategy is pursued, with a high coincident use of GP 
      IIb/IIIa antagonists. As the standard of care moves forward, we will see 
      increasing use of LMWHs, with and without GP IIb/IIIa antagonists in 
      conservatively and invasively managed patients.
FAU - Ferguson, James J
AU  - Ferguson JJ
AD  - St. Luke's Episcopal Hospital, Texas Heart Institute, University of Texas Health 
      Science Center at Houston, Baylor College of Medicine, Houston, Texas, USA. 
      jferguson@heart.thi.tmc.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Interv Cardiol
JT  - Journal of interventional cardiology
JID - 8907826
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
SB  - IM
MH  - Acute Disease
MH  - Clinical Trials as Topic
MH  - Coronary Thrombosis/drug therapy/*prevention & control
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
RF  - 32
EDAT- 2002/06/18 10:00
MHDA- 2002/07/18 10:01
CRDT- 2002/06/18 10:00
PHST- 2002/06/18 10:00 [pubmed]
PHST- 2002/07/18 10:01 [medline]
PHST- 2002/06/18 10:00 [entrez]
AID - 10.1111/j.1540-8183.2002.tb01047.x [doi]
PST - ppublish
SO  - J Interv Cardiol. 2002 Apr;15(2):147-54. doi: 10.1111/j.1540-8183.2002.tb01047.x.